Indra A. Van Assche

Indra A. Van Assche

Auto-generated profile, based on publicly available information

Indra A. Van Assche

Department of Development and Regeneration, Unit of Woman and Child, KU Leuven, Belgium

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
IAIndra A. Van Assche
Indra A. Van Assche
EVEvangeline A. Huis In 'T Veld
Evangeline A. Huis In 'T Veld
KCKristel Van Calsteren
Kristel Van Calsteren
MGMathilde van Gerwen
Mathilde van Gerwen
JBJeroen Blommaert
Jeroen Blommaert
FAFrédéric Amant
Frédéric Amant
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. This multicenter cohort study reports on the long-term effects of prenatal exposure to maternal cancer and its treatment on cognitive and behavioral outcomes in 9-year-old children. In total, 151 children (mean age, 9.3 years; range, 7.8-10.6 years) were assessed using a neurocognitive test battery and parent-report behavioral questionnaires. During pregnancy, 109 children (72.2%) were exposed to chemotherapy (only or in combination with other treatment modalities), 18 (11.9%) to surgery only, 16 (10.6%) to radiotherapy, one to trastuzumab, and 16 (10.6%) were not exposed to oncologic treatment. Mean cognitive and behavioral outcomes were within normal ranges. Gestational age at birth showed a positive association with Full Scale Intelligence Quotient (FSIQ), with the average FSIQ score increasing by 1.6 points for each week increase in gestational age (95% CI, 0.7 to 2.5; P < .001). No difference in FSIQ was found between treatment types (F[4,140] = 0.45, P = .776). In children prenatally exposed to chemotherapy, no associations were found between FSIQ and chemotherapeutic agent, exposure level, or timing during pregnancy. These results indicate a reassuring follow-up during the critical maturational period of late childhood, when complex functions develop and rely on the integrity of early brain development. However, associations were observed with preterm birth, maternal death, and maternal education.

13 June 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
FAFrédéric Amant
Frédéric Amant
FPFrançois Planchamp
François Planchamp
PBPaul Berveiller
Paul Berveiller
ECElyce Cardonick
Elyce Cardonick
AMAnne De Middelaer
Anne De Middelaer
MHMichael J. Halaska
Michael J. Halaska

19 March 2022 in Biological Psychiatry
Verified
Journal Article
Open access
AGAmy L. Gillespie
Amy L. Gillespie
CWChloe Wigg
Chloe Wigg
IAIndra Van Assche
Indra Van Assche
SMSusannah E. Murphy
Susannah E. Murphy
CHCatherine J. Harmer
Catherine J. Harmer
There is growing interest in the antidepressant potential of statins. We tested whether statin use is associated with cognitive markers previously found to indicate psychological vulnerability to depression within the context of the COVID-19 pandemic. Between April 2020 and February 2021, we conducted an observational online study of 2043 adults in the United Kingdom. Participants completed cognitive tasks assessing processes related to depression vulnerability, including affective bias and reward processing. We also measured working memory, medication use, and current psychiatric symptoms. Using mixed analysis of covariance and regression models, we compared participants on statins alone (n = 81), antihypertensive medication alone (n = 126), both medications (n = 111), and on neither medication (n = 1725). Statin use was associated with reduced recognition of angry and fearful faces (F1 = 9.19, p = .002; F1 = 6.9, p = .009) and with increased misclassification of these expressions as positive. Increased recognition of angry faces at baseline predicted increased levels of depression and anxiety 10 months later (β = 3.61, p = .027; β = 2.37, p = .002). Statin use was also associated with reduced learning about stimuli associated with loss (F1,1418 = 9.90, p = .002). These indicators of reduced negative bias were not seen in participants taking antihypertensive medication alone, suggesting that they were related to statin use in particular rather than nonspecific demographic factors. In addition, we found no evidence of an association between statin use and impairment in working memory. Statin use was associated with cognitive markers indicative of reduced psychological vulnerability to depression, supporting their potential use as a prophylactic treatment for depression.

10 November 2024 in eClinicalMedicine
Verified
Journal Article
Open access
IAIndra A. Van Assche
Indra A. Van Assche
KCKristel Van Calsteren
Kristel Van Calsteren
EVEvangeline A. Huis In ’T Veld
Evangeline A. Huis In ’T Veld
MGMathilde van Gerwen
Mathilde van Gerwen
LHLaura Heylen
Laura Heylen
FAFrédéric Amant
Frédéric Amant
Platina and taxanes are frequently used chemotherapeutic agents to treat cancer, also when diagnosed during pregnancy. This report presents an interim analysis of the largest series of children prenatally exposed to platinum and/or taxane agents and aims to determine their physical health and neurocognitive outcomes. As part of a multicentre, prospective cohort study (ClinicalTrials.gov: NCT00330447), children born between 2000 and 2022 were assessed between 2005 and 2024 at ages 1.5–18 years (interim analysis; median length of follow-up, 3.2 years (IQR 3.0–6.4)) by a comprehensive neurocognitive test battery, parent-reported questionnaires, and a physical assessment. Mixed-effects regression and Type III Analysis of Variance models were used to investigate associations between these outcomes and platinum/taxane cumulative dose and agent type, with best-fit models corrected for age and covariates (gestational age at birth, chemotherapy timing, other chemotherapy, sex, parental education level, maternal death). In total, 144 children were included (13% exposed to platinum, 62% to taxanes, 25% to both). Of these, 101 were assessed at age 1.5 years, 96 at age 3, 63 at age 6, 32 at age 9, 18 at age 12, 7 at age 15, and 2 at age 18 years. Neurocognitive outcomes were within normal ranges across all ages, compared with test-specific normative data. Eight children (6%) reported ototoxicity, seven (5%) reported chronic medical conditions, three (2%) had congenital malformations, and two (1%) were diagnosed with Attention-Deficit Hyperactivity Disorder. Thirty-three children (23%) needed extra neurocognitive support, of which 64% were born preterm. Children prenatally exposed to paclitaxel scored lower on visuospatial (β = 0.64 ± 0.21, p = 0.0052) and verbal memory (β = 0.68 ± 0.27, p = 0.015) than those exposed to docetaxel. In this interim analysis, we found normal neurocognitive outcomes and no increase in congenital malformations nor medical conditions after prenatal exposure to platinum/taxane-based chemotherapy. However, owed to the limited number of older children, further investigation regarding their potential neurotoxicity and its long term effects is necessary in follow-up studies with larger samples. 10.13039/501100011851 Kom Op Tegen Kanker , 10.13039/501100004622 KWF Kankerbestrijding , 10.13039/501100005026 Stichting Tegen Kanker , Cooperatio program, Research Foundation Flanders.

28 February 2024 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
EVEvangeline A. Huis In ’t Veld
Evangeline A. Huis In ’t Veld
IAIndra A. Van Assche
Indra A. Van Assche
FAFrédéric Amant
Frédéric Amant
The incidence of antenatal cancer is increasing, prompting a medical‐ethical evaluation. The International Network on Cancer, Infertility, and Pregnancy (INCIP) was established to study cancer treatment safety during pregnancy and its impact on maternal and child health. Pivotal research has led to a paradigm shift in clinical management, demonstrating the feasibility and safety of most antenatal oncological treatments. Short‐term outcomes reveal normal growth and cardiac function in the exposed offspring, but caution is advised against first‐trimester chemotherapy. Psychological impact studies highlight the elevated levels of distress in pregnant cancer patients, underscoring the need for personalized information and ongoing psychological support. Long‐term follow‐up studies address gaps in postnatal impacts, while research into specific chemotherapeutic agents continues. Despite generally reassuring outcomes, continued monitoring is crucial, especially in families, such as those where the child was born premature after cancer (treatment) during pregnancy or where mothers are frequently absent due to continued illness or have died from. The ongoing INCIP child follow‐up initiative aims to further elucidate knowledge gaps, emphasizing the importance of large‐scale studies and personalized patient care.

15 July 2025 in Annals of Oncology
Verified
Journal Article
Closed access
IAI.A. van Assche
I.A. van Assche
EVE. Huis In ‘t Veld
E. Huis In ‘t Veld
KCK. van Calsteren
K. van Calsteren
JLJ. Lemiere
J. Lemiere
TST. Salaets
T. Salaets
FAFrédéric Amant
Frédéric Amant